581106-33-4Relevant academic research and scientific papers
Acyloxyalkyl ester prodrugs of FR900098 with improved in vivo anti-malarial activity
Ortmann, Regina,Wiesner, Jochen,Reichenberg, Armin,Henschker, Dajana,Beck, Ewald,Jomaa, Hassan,Schlitzer, Martin
, p. 2163 - 2166 (2003)
FR900098 represents an improved derivative of the new antimalarial drug fosmidomycin and acts through inhibition of the 1-deoxy-D-xylulose 5-phosphate (DOXP) reductoisomerase, an essential enzyme of the mevalonate independent pathway of isoprenoid biosynt
Antibacterial and antitubercular activity of fosmidomycin, FR900098, and their lipophilic analogs
Uh, Eugene,Jackson, Emily R.,San Jose, Géraldine,Maddox, Marcus,Lee, Robin E.,Lee, Richard E.,Boshoff, Helena I.,Dowd, Cynthia S.
, p. 6973 - 6976 (2012/01/06)
The nonmevalonate pathway (NMP) of isoprene biosynthesis is an exciting new route toward novel antibiotic development. Inhibitors against several enzymes in this pathway are currently under examination. A significant liability of many of these agents is p
Alkoxycarbonyloxyethyl ester prodrugs of FR900098 with improved in vivo antimalarial activity
Ortmann, Regina,Wiesner, Jochen,Reichenberg, Armin,Henschker, Dajana,Beck, Ewald,Jomaa, Hassan,Schlitzer, Martin
, p. 305 - 314 (2007/10/03)
FR900098 represents a derivative of the new antimalarial drug fosmidomycin with enhanced activity. The mechanism of action is the inhibition of the 1-desoxy-D-xylulose 5-phosphate (DOXP) reductoisomerase, an essential enzyme of the mevalonate independent
